Modality
Peptide
MOA
USP1i
Target
KRASG12C
Pathway
JAK/STAT
Parkinson'sOvarian CaFabry
Development Pipeline
Preclinical
~Feb 2016
→ ~May 2017
Phase 1
~Aug 2017
→ ~Nov 2018
Phase 2
~Feb 2019
→ ~May 2020
Phase 3
~Aug 2020
→ ~Nov 2021
NDA/BLA
Feb 2022
→ Jan 2029
NDA/BLACurrent
NCT03556415
567 pts·Ovarian Ca
2022-02→2029-01·Recruiting
567 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-01-032.8y awayPh3 Readout· Ovarian Ca
Trial Timeline
2022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029
NDA/BLA
Recruit…
Catalysts
Ph3 Readout
2029-01-03 · 2.8y away
Ovarian Ca
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03556415 | NDA/BLA | Ovarian Ca | Recruiting | 567 | eGFR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-179 | Johnson & Johnson | Approved | KRASG12C | |
| BMY-4586 | Bristol-Myers Squibb | Preclinical | KRASG12C | |
| Doxarapivir | Bristol-Myers Squibb | Phase 3 | KRASG12C | |
| SNY-2934 | Sanofi | Phase 3 | KRASG12D | |
| AMG-4531 | Amgen | Phase 2/3 | KRASG12C | |
| AMG-9052 | Amgen | Phase 2/3 | CDK2 | |
| Datozumab | Regeneron | Phase 1 | B7-H3 | |
| REG-8074 | Regeneron | Phase 2/3 | KRASG12C | |
| VRT-1891 | Vertex Pharma | Phase 1 | KRASG12C | |
| Pemitapinarof | BeiGene | Approved | KRASG12C |